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Abstract
Epidemiologic evidence supports a genetic
predisposition to stroke. Recent advances, primarily
using the genome-wide association study approach,
are transforming what we know about the genetics of
multifactorial stroke, and are identifying novel stroke
genes. The current findings are consistent with
different stroke subtypes having different genetic
architecture. These discoveries may identify novel
pathways involved in stroke pathogenesis, and
suggest new treatment approaches. However, the
already identified genetic variants explain only a small
proportion of overall stroke risk, and therefore are not
currently useful in predicting risk for the individual
patient. Such risk prediction may become a reality as
identification of a greater number of stroke risk
variants that explain the majority of genetic risk
proceeds, and perhaps when information on rare
variants, identified by whole-genome sequencing, is
also incorporated into risk algorithms.
Pharmacogenomics may offer the potential for earlier
implementation of ‘personalized genetic’ medicine.
Genetic variants affecting clopidogrel and warfarin
metabolism may identify non-responders and reduce
side-effects, but these approaches have not yet been
widely adopted in clinical practice.
Review
Stroke: the scale of the problem
Stroke represents a major health problem. Every year in
the USA, 795,000 people experience a new or recurrent
stroke [1]. Mortality data from 2008 indicate that stroke
accounted for 1 in 18 deaths in the USA [1]. The Fra-
mingham Study showed that 1 in 5 women and 1 in 6
men aged 55 to 75 years will experience stroke some-
time during their life [2]. Although the incidence may
be reducing in developed countries, it has been esti-
mated that stroke mortality will double worldwide by
2020, owing to an ageing population and an increasing
incidence in developing countries.
Stroke is not only one of the major causes of death, but
is also the leading cause of long-term disability, making it
very costly to the economy. It has been estimated that
the cost of the 152,000 incident strokes annually in the
UK, and the cost of looking after patients who have had
previous stroke, is around £8 billion in total, including at
least £3 billion in direct healthcare costs [3].
Cerebrovascular disease (CVD) also causes vascular
dementia, which is not only an important cause of
dementia in its own right, but also seems to act synergis-
tically with Alzheimer’s disease pathology, increasing the
chance of resulting clinical dementia [4]. In addition,
CVD is the most common cause of adult-onset epilepsy,
and there is increasing evidence that vascular changes
contribute to late-onset depression [5].
Conventional cardiovascular risk factors are important
in stroke risk, and include hypertension, smoking, dia-
betes mellitus, hyperlipidaemia, and coexistent cardiovas-
cular disease including ischemic heart disease and atrial
fibrillation. However, conventional risk factors fail to
account for all stroke risk, as the proportion of unex-
plained risk has been estimated at about 50%, although
such estimates vary [6].
Stroke as a syndrome not a single disease
Stroke describes the clinical syndrome of focal neurologi-
cal loss of function, usually of sudden onset, resulting
from disturbance in the blood supply to the brain. It can
be caused by occlusion of, or hemorrhage from, a cere-
bral blood vessel. About 80% to 85% of stroke cases are
ischemic, whereas 15% to 20% are hemorrhagic.
Cerebral hemorrhage can be caused by multiple pathol-
ogies. Most cerebral hemorrhages are primary intracereb-
ral hemorrhages, and many of these are subcortical
hemorrhages associated with hypertension [7]. However,
many other pathologies can also cause intracerebral
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hemorrhage, including cerebral amyloid angiopathy and
underlying structural lesions. A minority of cerebral
hemorrhage cases results from subarachnoid hemor-
rhage, which is often associated with rupture of an intra-
cerebral aneurysm.
Not only can cerebral hemorrhage be caused by multi-
ple different pathologies, but ischemic stroke is also het-
erogeneous. The three main causes of ischemic stroke
are large-artery stenosis, small-vessel disease (SVD), and
cardioembolism [8].
• Large-artery stroke results from atherosclerotic pla-
que in the carotid, vertebral, or major intracerebral
arteries. Plaques, often associated with stenosis,
become unstable, resulting in formation of thrombus,
which subsequently embolizes distally to occlude cer-
ebral vessels.
• Cardioembolic stroke results from a variety of intra-
cardiac pathologies including atrial fibrillation, cardi-
omyopathy, and thrombus at the site of previous
myocardial infarction.
• SVD (lacunar stroke) affects the small perforating
arteries supplying subcortical structures, and results in
small lacunar infarcts affecting the white matter and
deep grey matter nuclei. The major risk factor for SVD
is hypertension, and the underlying pathologies
described include both diffuse small-vessel arteriopa-
thy (lipohyalinosis) and focal atheroma.
In addition to these three most common types of
ischemic stroke, there are many other rarer causes,
including carotid and vertebral dissection, vasculitis, and
single-gene disorders [8].
Identifying individual stroke subtypes requires detailed
investigation including brain imaging, imaging of the
extracerebral and intracerebral vessels, and cardiac ima-
ging. Despite this, in as many as 25% to 40% of patients
with ischemic stroke, an underlying pathology cannot be
found [9].
This heterogeneity of stroke implies that different
pathological mechanisms and risk factors are responsible
for different stroke subtypes. Recent genetic studies from
stroke are consistent with this, as described later.
The role of genetics in stroke risk
A number of single-gene disorders can result in both
ischemic and hemorrhagic stroke, and these tend to
cause specific stroke subtypes. The most common is cer-
ebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL), a mono-
genic cause of cerebral SVD. Although important to an
individual patient, these monogenic causes of stroke are
rare, and contribute little to overall population risk of
stroke. [10]
Epidemiological studies suggest that genetic risk factors
are important for common ‘sporadic’ stroke. The most
robust data on the heritability of a disease come from twin
studies, which have compared the incidence of stroke in
monozygotic compared with dizygotic twins. Twin studies
in stroke support a genetic predisposition, but the number
of stroke cases in prospective twin studies is small and
therefore, the confidence intervals are wide [11]. There is
much more information from family-history studies,
which show that a family history of stroke is more com-
mon in stroke cases than in stroke-free controls [11,12].
Such an association could be caused by recall bias, with
stroke cases more likely to have identified a family history
of stroke, but prospective data from the Framingham
Study, where information on family history was taken
before the onset of stroke, confirms this association [13].
However, an association with family history could also be
caused by shared early life environment, and separating
this from genetic risk is difficult. Family-history data sug-
gest that the genetic risk may vary by stroke subtype, with
stronger associations being reported for the large-artery
disease and SVD subtypes [12,14]
How can we identify genes for stroke?
Three main methods have been used; linkage, the candi-
date-gene approach, and genome-wide association studies
(GWAS). Linkage relies on identifying associations
between chromosomal markers and disease phenotype
within families. Linkage is good at identifying genes that
are associated with greatly increased risk, but is less suc-
cessful in more common polygenic diseases, in which mul-
tiple genes each contribute a small amount to overall risk.
Linkage techniques have identified many disease-causing
genes, but these have been primarily single-gene disorders.
Using linkage, a number of genes causing monogenic
stroke, such as the notch3 gene causing CADASIL, have
been discovered [15], but the technique has also been used
to look for variants contributing to polygenic stroke. This
approach found that variants in the phosphodiesterase 4D
gene PED4D were associated with ischemic stroke in an
Icelandic population, [16] but this could not be replicated
in other European populations, suggesting that it is either
not important in stroke as a whole, or is only important in
specific populations. [17]
Until recently, the main technique used to look for
genes predisposing to common stroke was the candidate-
gene method. Using this method, genetic variants, usually
single-nucleotide polymorphisms (SNPs), are identified in
a ‘candidate’ gene that is thought to be involved in stroke
risk. The frequency of the SNP is then compared between
stroke patients and controls, using a case-control
approach. Many candidate-gene studies on stroke have
been published. but the results have been largely disap-
pointing, with few associations replicated. This picture is
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common to the genetics of many other complex diseases.
The reasons for this lack of success have been explored
both in general, and specifically for stroke [18]. Impor-
tant factors are likely to include small sample sizes; a fail-
ure to replicate positive associations, coupled with
publication bias resulting in preferential publication of
positive associations; and a failure to phenotype cases
accurately. A further problem with candidate-gene stu-
dies is that associations can only be identified in genes
already known and implicated in stroke risk; completely
novel genes cannot be identified.
The field of complex genetics has been revolutionized by
the GWAS approach, which uses microarray technology to
genotype up to one million or more SNPs, spanning the
whole genome, in an individual subject [19]. A case-con-
trol or cohort approach is then used to compare the fre-
quency of individual SNPs between disease cases and
controls, and this is combined with rigorous statistical
multiple-comparison methods to account for the many
associations tested. Unlike the candidate-gene method,
GWAS allows associations between novel chromosomal
loci and disease to be identified. This technology has been
combined with a realization of the importance of both
very large sample sizes and the need to replicate positive
associations prior to publication. GWAS had resulted in
more than 1,600 novel associations with many complex
diseases being identified by September 2011 [20]. Novel
genetic associations have been reported in many CVDs
including myocardial infarction, hypertension, hyperlipide-
mia, and diabetes. Most genetic variants discovered using
GWAS account for only a small increase in disease risk,
with odds ratios (Ors) most often between 1.1 and 1.3.
This means that large sample sizes are required to identify
such variants, and has resulted in the formation of disease
consortiums that combine data from multiple studies in
meta-analyses. Some of these now have 50,000 or more
samples, allowing identification of variants with progres-
sively smaller ORs.
Genome-wide association studies in stroke
GWAS in stroke have lagged behind those in other
CVDs, perhaps because the heterogeneity of the stroke
phenotype was thought to make the chance of success
less likely; however, the approach is now identifying
novel genetic variants for stroke. In this brief review, I
will focus on ischemic stroke, although advances are also
being made in cerebral hemorrhage and in the genetics
of intracranial aneurysms.
Initial studies attempted to replicate GWAS associa-
tions that had been initially found in other diseases
associated with increased stroke risk. Two variants
(PITX2 and ZFHX3), which were initially associated
with atrial fibrillation, have both been shown to be inde-
pendent risk factors for ischemic stroke; associations are
only apparent with cardioembolic stroke and not with
other stroke subtypes [21,22]. A variant at chromosome
9p21, which was originally associated with myocardial
infarction and coronary artery disease [23], was found to
be associated with ischemic stroke across multiple popu-
lations, but this association was present only with large
artery stroke [24].The same locus has been associated
with aortic and intracranial aneurysms [25].
There have been fewer novel GWAS associations initi-
ally identified in stroke itself, although a number of large
GWAS in ischemic stroke are now taking place. Recently,
the Wellcome Trust Case Control Consortium 2 ischemic
stroke GWAS identified a novel association at 7p21; the
most likely underlying gene is HDAC9, encoding histone
deacetylase 9 [26].This association was confined to the
large artery stroke subtype. HDAC9 is a member of a large
family of genes that encode proteins responsible for deace-
tylation of histones, and therefore regulate chromatin
structure and gene transcription. The mechanism by
which variants in HDAC9 increase large artery stroke risk
is not immediately clear, although the specific association
with large artery stroke might suggest that they act
through increasing atherogenesis. Sodium valproate,
which has HDAC inhibitory properties, has been shown to
inhibit atheroclerosis in animal models [27], and intrigu-
ingly, sodium valproate therapy in humans has been asso-
ciated with lower stroke and myocardial infarction rates
compared with other anti-epileptics [28].
A GWAS on Japanese cases with ischemic stroke iden-
tified an SNP in a member of the protein kinase (PKC)
family, PRKCH, which was associated with small-vessel
stroke [29]. This was replicated in an independent
cohort, and the association has been further replicated in
a Chinese population [30], and also with MRI-deter-
mined silent brain infarction [31]. PRKCH is a serine/
threonine kinase that regulates a variety of cellular func-
tions including differentiation, proliferation, and apopto-
sis [29]. The SNP identified is very rare in white
populations, and whether it contributes to disease risk in
populations other than Japanese and Chinese, or whether
the association can be replicated more widely, remains to
be determined.
Most studies to date have used a case-control design.
This design could be open to bias if the gene in question
is associated with early mortality in a disease such as
stroke, where there is a significant early mortality, and if
samples are collected only from survivors. Cohort stu-
dies, in which subjects are followed for many years and
those developing stroke are compared with those remain-
ing stroke-free, avoid this bias; however such studies tend
to have smaller numbers of stroke, and also subtyping
can be difficult as the strokes may occur in multiple hos-
pitals. A meta-analysis of prospective cohort GWAS
studies reported an association with the 12p13 region
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[32], but this could not be replicated in a much larger
case-control study [33] or in a second Swedish study
[34]. This could be because the variant is associated with
stroke mortality, but it could also represent a false-posi-
tive association.
An alternative design is to genotype more than one
family member and use family-based analysis methods.
These can involve parent and offspring trios or more
extensive family structures, or be based on sibling pairs.
The former are difficult to collect for a late-onset dis-
ease such as stroke; affected sibling-pair collections are
more realistic, but even collecting these in stroke is
challenging, and obtaining the large sample sizes
required for GWAS has proved difficult [35].
In summary, GWAS studies have identified a few robust
associations with ischemic stroke. The associations found
to date have been for specific stroke subtypes, emphasizing
the importance of careful phenotyping, and suggesting
that different stroke subtypes have different pathophysio-
logic mechanisms and genetic risk-factor profiles.
The largest GWAS studies in stroke to date have com-
prised about 3,000 cases. Larger studies are underway. The
Stroke Genetics Network (SiGN) study, funded by the
National Institute of Neurological Disorders and Stroke,
aims to genotype at least a further 6,000 cases. The Metas-
troke collaboration has brought together groups with
GWAS data on ischemic stroke from throughout the
world, and currently comprises about 14,000 cases and
50,000 controls.
Future advances
Meta-analysis of GWAS data from tens of thousands of
patients with stroke is likely to identify further variants,
as it has for other complex diseases. If variants do indeed
predispose to specific stroke subtypes, then even larger
sample sizes may be required. For example, even though
a sample size of 10,000 sounds large, it will only include
approximately 2,000 individuals with large artery stroke.
The GWAS approach is suited to identify common var-
iants, each of which contribute a small amount to disease
risk. It is less effective at detecting rare variants, which
might still be important in disease risk. Whole-genome
sequencing enables these rare variants to be identified, and
the cost of this technique is rapidly falling [36]. As yet,
results are not available from this approach for stroke,
although studies are underway. Many current sequencing
studies limit coverage to sequencing of the exome, or pro-
tein coding part, of the genome. Exome sequencing has
been successful in many rare, primarily monogenic, dis-
eases and may offer a cost-effective way to screen for mul-
tiple single-gene causes of stroke in one assay. Studies are
underway using exome sequencing to try to identify rare
variants that may contribute to more common polygenic
diseases [37]. Such studies may particularly benefit from
the use of family-based approaches, to help separate causal
from non-causal variants.
Another emerging area is epigenetics, although to date
there have been few studies for stroke. Epigenetics
describes the study of heritable changes in gene expression
or cellular phenotype, which are caused by mechanisms
other than changes in the underlying DNA sequence [38].
It therefore refers to functionally relevant modifications in
the genome that do not involve the changed nucleotide
sequence. Examples of such changes are DNA methylation
and histone modification, both of which serve to regulate
gene expression without altering the DNA structure.
Methods are now becoming available to assess epigenetic
changes. For example, array-based methods can be use for
typing DNA methylation in large populations, and case-
control studies similar to those being performed for
GWAS are beginning to reveal interesting results [39].
How can identifying genes for stroke help patients?
Even though monogenic stroke is rare, identifying the
underlying gene can be important for the individual
patient. In such diseases, a mutation in a specific gene
results in disease, and most individuals with the mutation
are likely to develop stroke or other clinical presentations
of the disease at some stage in their life. Identifying the
underlying mutation allows diagnosis, information on
prognosis, and in some cases, specific treatments. It also
enables counseling of other family members, and prenatal
testing if desired. However, many monogenic forms of
stroke are untreatable, and therefore, specialized genetic
counseling is important before mutation testing. This is
particularly important in asymptomatic individuals, or
those with mild disease; for example, potential CADASIL
patients who have migraine but have not yet developed
stroke or dementia.
However, the vast majority of stroke is ‘polygenic’, with
many genes thought to be involved, each conferring a
small risk and probably interacting with multiple envir-
onmental risk factors to cause disease. How can such
genetic knowledge benefit patients? Can we really offer
personalized medicine in which the genetic profile in an
individual provides useful information on stroke risk?
Genetic testing for polygenic diseases is already being
developed, and indeed, some gene tests for cardiovascular
disease have already been marketed, with the individual
purchasing a test online and sending off a saliva swab for
DNA extraction and testing for a number of at-risk
SNPs. However, the clinical use of such tests has been
questioned. Genetic epidemiological studies have sug-
gested that the sibling relative risk for stroke is approxi-
mately 2 to 3, with the higher estimate applying if
younger patients are considered [40]. Assuming that the
genetic variants identified confer ORs of between 1.1 and
1.2, it has been calculated that 100 to 300 different
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genetic variants explain this degree of risk [41]. There-
fore, panels that include only 5 to 10 or so variants will
explain only a small proportion of overall disease risk
and so be poor disease predictors. The genetic variants
for stroke described to date account for only a small pro-
portion of overall stroke risk. Therefore, even when com-
bined, their predictive value is low, and even if an
individual has these variants, they may not develop stroke
during their lifetime, whereas people without these var-
iants could be at risk of stroke. Until we have a more
complete understanding of the molecular basis of genetic
variation, such predictive testing is likely to provide lim-
ited information.
There are also questions about the usefulness of such
personalized testing in patients with complex diseases
such as stroke. We already know many risk factors for
stroke, such as hypertension and smoking, but despite
their importance, patient compliance is often suboptimal.
Unless there are specific novel treatments for individual
genetic variants, it is likely that the advice given to a
patient identified as having a high genetic risk of stroke
would merely be to adhere more closely to cardiovascular
risk-factor prevention, yet it is unclear whether such
high-risk patients would indeed do so. Furthermore,
there is the possibility that patients deemed to have low
genetic risk might pay less attention to general risk-factor
prevention and therefore, expose themselves to increased
risk. There has also been concern over the psychological
consequences of testing.
Therefore, the clinical use of genetic profiling of stroke
risk is likely to be some way in the future. In the more
immediate future, identifying novel genetic variants may
contribute to treating disease by identifying new path-
ways involved in the pathogenesis of stroke. Using infor-
mation gained from GWAS to develop novel treatments
for complex diseases is beginning to bear fruit in other
diseases such as macular degeneration and Crohn’s dis-
ease [42,43]. One criticism is that the genetic associations
identified are unlikely to be important in view of the
small increase in risk (OR) associated with each one.
However, it is relevant that the total variance in disease
risk explained by genes involved in pathological processes
targeted by already established successful currently avail-
able drugs, such as statins for hypercholesterolaemia, sul-
fonylureas for diabetes, and estrogens for bone density, is
often small [44].
Pharmacogenomics
One area where personalized genetic medicine may have
earlier application is pharmacogenomics. Genetic varia-
tion influences drug metabolism, and thus both drug effi-
cacy and risk of drug-related adverse effects (AEs).
Pharmacogenomics uses an individual’s genotype to assist
in choosing therapies and identifying the optimal dose,
with the aim of ensuring maximum efficacy with minimal
AEs [45]. In addition, it can provide new insights into the
mechanisms of drug action, and therefore contribute to
the development of new therapeutic agents. As yet, phar-
macogenomics has had little effect on routine clinical
stroke care in most countries, but two potential applica-
tions in tailoring anti-platelet therapy and warfarin
dosage in patients with CVD, including stroke, have been
proposed, for the drugs clopidogrel and warfarin.
Clopidogrel
Clopidogrel is widely used for prevention of secondary
stroke. It is more effective than aspirin alone [46], and has
similarly effectiveness to the combination of aspirin and
dypridamole in long-term secondary prevention [47].
Approximately 5 to 30% of clopidogrel-treated patients
exhibit low or no reactivity to clopidogrel, which is
referred to as ’clopidogrel resistance.’ Clopidogrel requires
transformation into an active metabolite by cytochrome
P450 (CYP) for its anti-platelet effect. Different CYP isoen-
zymes are responsible for clopidogrel activation, and
among these, CYP2C19 has been found to play a key role.
Carriers of at least one CYP2C19*2 reduced-function allele
(about 25 to 30% of the population) have a one-third
reduction in the active metabolite of clopidogrel compared
with non-carriers, whereas the 2% of individuals homozy-
gous for the polymorphism have a much greater reduction
[48]. The variant has been associated with a corresponding
reduction in platelet inhibition [48].
A number of reports have suggested that this variant
was associated with increased cardiovascular events in
patients on clopidogrel, particularly after coronary stent-
ing, where there is a high risk of stent thrombolysis. This
led to the US Food and Drug Administration (FDA)
announcing in 2010 that clopidogrel would receive a
boxed warning in the prescribing information, which
cautioned that slow metabolism of clopidogrel was asso-
ciated with higher cardiovascular event rates, and sug-
gested that genetic testing could identify individuals who
were slow metabolizers, thereby allowing physicians to
implement ‘alternative treatment strategies.’ [49]. This
FDA announcement was controversial. The American
Heart Association (AHA) and American College of Car-
diology (ACC) issued a consensus statement that con-
cluded ‘The evidence base is insufficient to recommend
either routine genetic or platelet function testing at the
present time’ [50]. This controversy has continued, with
arguments being made both for [51] and against [52]
testing, although these have been primarily applied to
treatment in stented individuals and not in non-stented
patients with coronary ischaemia or patients with stroke.
A recent systematic review and meta-analysis identified
32 studies of 42,016 patients reporting 3,545 cardiovascu-
lar events and 1,413 bleeding events [53]. Six studies
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were randomized trials with comparison against another
treatment (effect-modification design) whereas the
remaining 26 studies comprised individuals exposed to
clopidogrel with no control arm (treatment-only design).
In the analysis of treatment-only studies, individuals with
one or more CYP2C19 alleles had a lower risk of bleed-
ing, and a higher risk of cardiovascular events. However,
when analyses were restricted to studies with 200 or
more events, the association was no longer significant,
consistent with publication bias. In studies that included
a control arm, the CYP2C19 genotype was not associated
with modification of the effect of clopidogrel on cardio-
vascular end points or bleeding.
Even if an association can be shown between a genetic
variant and drug efficacy, the most powerful evidence for
the use of such a genetic test in clinical practice is a ran-
domized, controlled trial that compare a strategy of mod-
ifying treatment, based on the results of genetic
screening, with standard care (that is, no testing). Such
trials will not only provide reliable estimates of the effect
of genotype on drug response but will also take into
account the potential effect of the testing procedure itself
on patient outcomes [52].
Most studies of the CYP2C19 polymorphisms have
been in coronary artery disease, but in a genetic substudy
of the Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management, and Avoidance
(CHARISMA) study, about 20% of the 4,819 genotyped
patients had ischemic stroke at entry [54]. Carriers of
CYP2C19 loss-of-function alleles did not have an
increased rate of ischemic events, but did have a signifi-
cantly lower rate of any bleeding when on clopidogrel.
The story of a personalized pharmacogenomic approach
to clopidogrel therapy illustrates the difficulties in imple-
menting such an approach, and the need for rigorous
assessment of its benefit and effect on clinical outcome.
This does not mean that the approach may not prove use-
ful in the longer term. The CYP2C19 loss-of-function
alleles account for only 12% of the variability in response
to clopidogrel, whereas 72% of the variability is heritable
[52]. Genetic testing of a wider range of variants that
better captures this heritability is likely to provide more
predictive information.
Warfarin
Warfarin reduces the risk of stroke in patients with non-
valvular atrial fibrillation, and is also used in patients with
other cardiac lesions associated with a high risk of cardi-
oembolism, including prosthetic heart valves and mural
thrombus. The high variability in drug response means
that blood monitoring of coagulation with the interna-
tional normalized ratio (INR) is required, but there is
a narrow therapeutic index, and there is a risk of thrombo-
sis with under-anti-coagulation and of hemorrhage with
over-anti-coagulation. Warfarin is the second leading
drug-related reason for emergency department visits [55],
and the most frequently cited reason for drug-related mor-
tality [56]. Therefore, methods to improve the safety and
effectiveness of warfarin therapy would have wide
application.
A number of genetic variants have to shown to influence
warfarin levels [45]. Warfarin is a racemic mixture, with S-
warfarin being more potent than R-warfarin. CYP2C9 is a
hepatic drug-metabolizing enzyme in the CYP450 super-
family, and is the primary metabolizing enzyme of S-war-
farin. Two common CYP2C9 allozymes have markedly
reduced enzyme activity. It was shown that patients who
required a low final dose of warfarin on the basis of INR
values often carried one or two of these two common
CYP2C9 variant alleles, and were at increased risk for
hemorrhage during warfarin therapy, presumably because
they metabolize the drug more slowly [45]. Vitamin K
epoxide reductase complex subunit 1, is the target for war-
farin-based anticoagulants, and SNPs in the VKORC1 gene
are also associated with the dose of warfarin required to
achieve a target INR value. Together, the CYP2C9 and
VKORC1 polymorphisms explain about 30 to 40% of the
total variation in the final warfarin dose [57].
To assess the added contribution of testing for these
genetic variants, the clinical and genetic data from 4,043
patients were used to create a dose algorithm that was
based on clinical variables only, and an algorithm in
which genetic information was added to the clinical vari-
ables [58]. This was validated in a second cohort of 1,009
subjects. Use of the pharmacogenetic algorithm produced
dose recommendations that were significantly closer to
the required stable therapeutic dose than those derived
from the clinical algorithm, particularly for patients who
required unusually high or low warfarin doses.
Supporting this approach, a mulitcenter national study
prospectively collected data on rate of hospitalization over
a 6-month period in 896 patients receiving warfarin geno-
typing, and compared this with 2,688 matched historical
controls [59]. The genotyped cohort had 31% fewer hospi-
talizations overall, and 28% fewer hospitalizations for
bleeding or thromboembolism.
In February 2010, the FDA revised the label on warfarin,
providing genotype-specific ranges of doses, and suggest-
ing that genotypes be taken into consideration when the
drug is prescribed. CYP2C9 and VKORC1 genotyping is
now clinically available. as are online and web-based algo-
rithms incorporating genotypic information to calculate
dosage [60]. Despite this, implementation of this genetic
testing in clinical practice has been slow. It has been
argued that a truly randomized trial is required to confirm
the effect on clinical management and to examine cost-
effectiveness. In addition, new anticoagulants with a wider
therapeutic range and acting by different mechanisms
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have been shown to be as effective as warfarin in stroke
prevention, and may be preferred for patients for whom
warfarin therapy is difficult or has anticipated side-effects.
Promise of pharmacogenomics
The cases of clopidogrel and warfarin demonstrate the
promise of pharmacogenomics, but also the difficulties in
evaluating the clinical effect of such an approach. With
the increasing reliance on evidence-based medicine and
large randomized trials, it is likely that a similar degree of
evidence will be required before such approaches are
widely implemented. Nevertheless, this is an area that
could significantly improve targeting of therapies and
reduce side-effects.
Conclusions
Epidemiologic evidence supports genetic factors being
important in stroke risk. Recent advances, primarily
GWAS, are transforming what we know about the genet-
ics of multifactorial stroke, and are identifying novel stroke
genes. The findings to date suggest that different stroke
subtypes have different genetic architecture. Novel genes
associated with stroke may identify novel pathways
involved in stroke pathogenesis, and suggest new treat-
ment approaches. The already identified genetic variants
explain only a small proportion of overall stroke risk, and
therefore are not currently useful in predicting risk in the
individual patient. Predicting stroke risk in the individual
patient may become a possibility if a greater number of
stroke risk variants that explain the majority of genetic
risk can be identified, and if information on rare variants,
identified by whole-genome sequencing, is also incorpo-
rated into risk algorithms. Pharmacogenomics may offer
the potential for earlier implementation of ‘personalized
genetic’ medicine. Genetic variants affecting clopidogrel
and warfarin metabolism may identify non-responders and
reduce side-effects, but their use has not yet been widely
adopted in clinical practice.
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